Tempest Therapeutics Q3 Loss Hits $3.6M as Cash Falls to $897K

Tempest Therapeutics (Nasdaq: TPST) reported a net loss of $3.6 million, or $0.21 per share, for the third quarter ended September 30, 2026, and closed the period with $897,000 in cash and cash equivalents, down from $7.7 million at December 31, 2025. The company said in its November 13, 2026 press release that its existing cash will fund projected operating expenses for less than 12 months, and that substantial doubt exists about its ability to continue as a going concern. Tempest also disclosed a September 2026 private placement raising roughly $2.5 million in gross proceeds.

Context — Why Tempest's Going-Concern Warning Matters Now

Tempest is a clinical-stage biotech that has pivoted its entire pipeline toward in vivo CAR-T therapies, a capital-intensive modality with no approved products anywhere in the class. The company's cash position of $897,000 is a fraction of its $8.8 million in total assets, meaning the balance sheet is now dominated by operating lease right-of-use assets rather than deployable capital.

The trigger for the current funding situation traces to February 2026, when Tempest completed an Asset Acquisition that pulled it out of its prior small-molecule strategy and into in vivo CAR-T. That transaction produced $22.2 million in acquired in-process research and development expense during the nine months ended September 30, 2026, versus nil in the prior-year period.

The company has been stacking small financings to bridge the gap. A March 2026 private placement brought in $1.7 million, a May 2026 warrant inducement added another $1.7 million, and a September 2026 private placement contributed $1.8 million net. An August 2026 Lincoln Park equity line of credit gives Tempest the right, but not the obligation, to sell up to $25 million of common stock, rising to $50 million if the initial tranche is sold.

For a Nasdaq-listed biotech, a going-concern qualification in a quarterly release is a material disclosure that forces investors to weigh near-term financing risk against clinical optionality. The company did not disclose terms of any additional committed financing beyond the Lincoln Park facility.

Data — What the Numbers Show

The headline comparison is the cash burn trajectory. Cash and cash equivalents fell from $7.7 million at December 31, 2025 to $897,000 at September 30, 2026, a decline of roughly $6.8 million over nine months. Cash used in operating activities for that same period was $12.4 million, meaning the burn outpaced the period-end cash decline because of offsetting financing inflows.

Third-quarter research and development expense was $207,000, down from $570,000 a year earlier. General and administrative expense was $2.6 million versus $3.0 million. The quarter's net loss of $3.6 million compared to $3.5 million in Q3 2025, but the per-share loss narrowed to $0.21 from $0.79 because the share count expanded.

Metric	Q3 2026	Q3 2025
Net loss	$3.6M	$3.5M
Net loss per share	$0.21	$0.79
R&D expense	$0.2M	$0.6M
G&A expense	$2.6M	$3.0M

For the nine months ended September 30, 2026, net loss was $36.6 million, or $2.54 per share, versus $22.2 million, or $5.71 per share, in the prior-year period. The nine-month figure includes the $22.2 million acquired IPR&D charge and $806,000 in financing costs tied to the Lincoln Park equity line.

Analysis — What It Means for Biotech Investors

The immediate read is that Tempest's cash runway depends almost entirely on its ability to tap the Lincoln Park facility or raise fresh equity. Through September 30, 2026, the company had sold only 350,000 shares to Lincoln Park for about $0.3 million in gross proceeds — a small fraction of the $25 million initial capacity. That slow draw suggests limited appetite or limited utility at current price levels.

Second-order effects land on the broader in vivo CAR-T peer group, where capital markets have rewarded companies with partnered pipelines and penalized those funding solo. Tempest's July 2026 strategic partnership with Hebei Senlang Biotechnology, covering TPST-4003 development and an investigator-initiated trial in China, is the kind of structure that can shift development costs off the primary balance sheet — but the company did not disclose the financial terms.

The counter-argument is that biotech going-concern warnings are common and often resolved through subsequent financings. Tempest's accumulated deficit of $278.9 million against total stockholders' equity of negative $1.8 million shows how much capital has already been consumed. Positive equity depends on continued access to the equity line and warrant exercises.

Positioning-wise, the shareholder base is likely dominated by retail and event-driven holders given the sub-$1 stock behavior implied by the per-share loss math, while institutional investors typically avoid names with going-concern qualifications unless a catalyst is imminent.

Outlook — What to Watch Next

The company's stated near-term catalyst is initial Phase 1 data for TPST-4903, its BCMA/GPRC5D dual-targeting in vivo CAR-T candidate in relapsed or refractory multiple myeloma, which the company said is expected at an upcoming scientific conference. No date was disclosed.

A second catalyst is the investigator-initiated trial in China for TPST-4003 in approximately 10 patients with myasthenia gravis or multiple sclerosis, which the company expects to begin in the fourth quarter of 2026.

On the financing side, watch the pace of Lincoln Park draws. Any acceleration in share sales would signal deepening cash pressure; continued slow draws would suggest the facility is not a sufficient bridge. Tempest did not provide a specific cash runway end date.

Frequently Asked Questions

What does the going-concern warning mean for Tempest Therapeutics shareholders?

A going-concern qualification means Tempest's auditors and management have concluded there is substantial doubt the company can fund operations for at least 12 months from the financial statement issuance date. It does not mean immediate insolvency. It typically forces the company to raise capital, cut programs, or find a partner. Tempest's $897,000 cash balance and $12.4 million nine-month operating cash burn illustrate the scale of the gap it must close.

How did Tempest fund itself during 2026?

Tempest completed three separate financings in 2026: a March private placement of $1.7 million, a May warrant inducement of $1.7 million, and a September private placement of roughly $2.5 million gross, or about $1.8 million net. It also established a Lincoln Park equity line in August 2026 worth up to $50 million, though it had drawn only about $0.3 million through September 30, 2026. The company did not disclose pricing on any of these transactions.

What is TPST-4903 and why does it matter for Tempest?

TPST-4903 is Tempest's lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate, being tested in a Phase 1 dose-escalation study in relapsed or refractory multiple myeloma. Tempest exercised an option in 2026 to exclusively license the underlying CD7-targeted lentiviral platform from Hebei Senlang Biotechnology, excluding China rights. Initial clinical data are expected at an upcoming scientific conference, though no date or venue was disclosed.

Bottom Line

Tempest's pipeline progress is real, but $897,000 in cash against a going-concern warning makes the next financing the only story that matters.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.